

DAFTAR KEPUSTAKAAN

1. International AD. Dementia Statistics [Internet]. 2020. Available from: <https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/>
2. WHO. Dementia [Internet]. who.int. 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/dementia>
3. Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-Onset Alzheimer's Disease: What Is Missing in Research? *Curr Neurol Neurosci Rep.* 2021;21(2).
4. Purba JS. Inflamasi dalam Patologi Penyakit Alzheimer. *Medicinus.* 2020;33(3):65–71.
5. Anwal L. a Comprehensive Review on Alzheimer'S Disease. *World J Pharm Pharm Sci.* 2021;10(7):1170.
6. Lane CA, Hardy J, Schott JM. Alzheimer's disease. *Eur J Neurol.* 2018;25(1):59–70.
7. Indonesia A. Statistik Tentang Demensia [Internet]. 2019. Available from: <https://alzi.or.id/statistik-tentang-demensia/>
8. Cobourne-Duval MK, Taka E, Mendonca P, Soliman KFA. Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFN γ -activated BV-2 microglia cells. *J Neuroimmunol.* 2018;320:87–97.
9. Immunotherapy II-, Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. 2018;1–15.
10. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. *Immunity* [Internet]. 2019;50(4):1007–23. Available from: <https://doi.org/10.1016/j.immuni.2019.03.026>
11. Saiki P, Nakajima Y, Van Griensven LJLD, Miyazaki K. Real-time monitoring of IL-6 and IL-10 reporter expression for anti-inflammation activity in live RAW 264.7 cells. *Biochem Biophys Res Commun* [Internet]. 2018;505(3):885–90. Available from: <https://doi.org/10.1016/j.bbrc.2018.09.173>
12. Lyra e Silva NM, Gonçalves RA, Pascoal TA, Lima-Filho RAS, Resende E de PF, Vieira ELM, et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. *Transl Psychiatry* [Internet]. 2021;11(1). Available from: <http://dx.doi.org/10.1038/s41398-021-01349-z>
13. Sawkulycz X, Bradburn S, Robinson A, Payton A, Pendleton N,

Murgatroyd C. Neurobiology of Aging Regulation of interleukin 6 by a polymorphic CpG within the frontal cortex in Alzheimer ' s disease. *Neurobiol Aging* [Internet]. 2020;92:75–81. Available from: <https://doi.org/10.1016/j.neurobiolaging.2020.04.008>

14. Wilson H, Pagano G, Politis M. Dementia spectrum disorders: lessons learnt from decades with PET research. *J Neural Transm* [Internet]. 2019;126(3):233–51. Available from: <http://dx.doi.org/10.1007/s00702-019-01975-4>
15. Liu XY, Yang LP, Zhao L. Stem cell therapy for alzheimer's disease. *World J Stem Cells*. 2020;12(8):787–802.
16. Ota KI. Fuel Cells: Past, Present and Future. *IEEJ Trans Fundam Mater*. 2008;128(5):329–32.
17. Isaacson RS, Ganzer CA, Hristov H, Hackett K, Cohen R, Kachko R, et al. HHS Public Access. 2019;14(12):1663–73.
18. Mendez MF. Early-Onset Alzheimer Disease. *Neurol Clin*. 2017;35(2):263–81.
19. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention. *J Prev Alzheimer's Dis*. 2021;8(3):313–21.
20. Scheyer O, Rahman A, Hristov H, Berkowitz C, Isaacson RS, Diaz Brinton R, et al. Female Sex and Alzheimer's Risk: The Menopause Connection. *J Prev Alzheimer's Dis*. 2018;5(4):225–30.
21. Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mcguire LC. racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged \geq 65 years.pdf. 2020;15(1):17–24.
22. Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. *Alzheimer's Dement* [Internet]. 2020;16(11):1553–60. Available from: <https://doi.org/10.1016/j.jalz.2019.09.075>
23. Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, et al. Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. *J Prev Alzheimer's Dis*. 2019;6(1):2–15.
24. Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in alzheimer's disease: A review on emergent natural polyphenolic therapeutics. *Complement Ther Med* [Internet]. 2020;49(December 2019):102294. Available from: <https://doi.org/10.1016/j.ctim.2019.102294>

25. Squitti R, Faller P, Hureau C, Granzotto A, White AR, Kepp KP. Unco rrecte d Au tho r P Copper Imbalance in Alzheimer ' s Disease roo f co rrecte d Au tho r P roo f. 2021;
26. Esmieu C, Guettas D, Conte-Daban A, Sabater L, Faller P, Hureau C. Copper-Targeting Approaches in Alzheimer's Disease: How to Improve the Fallouts Obtained from in Vitro Studies. *Inorg Chem.* 2019;58(20):13509–27.
27. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: From risk factors to early intervention. *Alzheimer's Res Ther.* 2017;9(1):1–9.
28. Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, et al. On the path to 2025: Understanding the Alzheimer's disease continuum. *Alzheimer's Res Ther.* 2017;9(1):1–10.
29. Armstrong RA. Risk factors for alzheimer disease. [Factores de riesgo para la enfermedad de Alzheimer]. *Brain and Nerve.* 2019;57(2):87–105.
30. Singh NA, Bhardwaj V, Ravi C, Ramesh N. EGCG Nanoparticles Attenuate Aluminum Chloride Induced Neurobehavioral Deficits , Beta Amyloid and Tau Pathology in a Rat Model of Alzheimer ' s Disease. 2018;10(August):1–13.
31. Budiman HM, Berawi KN, Bustomi EC, Kedokteran F, Lampung U, Fisiologi B, et al. Mekanisme Rokok dalam Meningkatkan Risiko Penyakit Alzheimer Smoking Mechanism in Increasing Risk of Alzheimer ' s Disease. 2018;7:234–40.
32. Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. *Med Clin North Am* [Internet]. 2019;103(2):263–93. Available from: <https://doi.org/10.1016/j.mcna.2018.10.009>
33. Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. *Mol Neurodegener.* 2019;14(1):1–18.
34. Kumar Thakur A, Kamboj P, Goswami K, Ahuja K. Pathophysiology and management of alzheimer's disease: an overview. *J Anal Pharm Res.* 2018;7(2):226–35.
35. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain.* 2018;141(7):1917–33.
36. Tiwari S, Venkata A, Kaushik A, Adriana Y, Nair M. Alzheimer ' s Disease Diagnostics And Therapeutics Market. *Int J Nanomedicine .* 2019;Jul 2019(14):5541–54.
37. Ada N, Wilson WT, Zhang MW, Ho CS, Husain SF. IL-1 β , IL-6 , TNF- α and CRP in Elderly Patients with Depression or Alzheimer ' s disease :

Systematic Review and Meta-Analysis. 2018;(August 2017):1–12.

38. Tawfig N. Proinflammatory Cytokines and Periodontal Disease. *J Dent Probl Solut*. 2016;3:012–7.
39. Tanaka T, Narazaki M, Kishimoto T. patterns (DAMPs), which are released from damaged or dying cells in noninfectious inflammations such as burn or trauma, directly or indirectly promote inflammation. During sterile surgical operations, an increase in serum IL66 levels precedes elevation of. 2014;6(Kishimoto 1989):1–16.
40. Haddick PCG, Larson JL, Rathore N, Bhangale TR, Phung QT, Srinivasan K, et al. A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer’s Disease Brains. *J Alzheimer’s Dis*. 2017;56(3):1037–54.
41. Kim YS, Lee KJ, Kim H. Serum tumour necrosis factor- α and interleukin-6 levels in Alzheimer ’ s disease and mild cognitive impairment. 2017;1–7.
42. Zhao J, Liu P, Hua L, Yang X, Zeng Z, Li X, et al. Haplotype analysis on association between variants of interleukin 6 (IL-6) and late-onset Alzheimer’s disease in a Chinese Han population. *Exp Gerontol* [Internet]. 2020;131(November 2019):110813. Available from: <https://doi.org/10.1016/j.exger.2019.110813>
43. Yang R, Duan J, Luo F, Tao P, Hu C. IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer’s disease: a meta-analysis. *Acta Neurol Belg* [Internet]. 2021;121(6):1505–12. Available from: <https://doi.org/10.1007/s13760-020-01369-4>
44. Naaldijk Y, Jäger C, Fabian C, Leovsky C, Blüher A, Rudolph L, et al. Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. *Neuropathol Appl Neurobiol*. 2017;43(4):299–314.
45. Costa-Marques L, Arnold K, Pardon MC, Leovsky C, Swarbrick S, Fabian C, et al. Transplantation of bone marrow derived macrophages reduces markers of neuropathology in an APP/PS1 mouse model. *Transl Neurodegener*. 2019;8(1):1–11.
46. Yeram N, Dalvi S, Mankeshwar R, Patil V, Kale V, Jagiasi K, et al. Relationship between cortisol , Interleukin-6 and homocysteine in Alzheimer ’ s disease. 2021;2021:1–7.
47. Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. *Alzheimer’s Res Ther*. 2019;11(1):1–14.
48. Jin H, Guan S, Wang R, Fang X, Liu H, Wu Y, et al. The Distribution of Urinary Alzheimer-Associated Neuronal Thread Protein and Its Association with Common Chronic Diseases in the General Population. *J Alzheimers*

Dis. 2018;65(2):433–42.

49. Reza-Zaldivar EE, Hernández-Sapiéns MA, Minjarez B, Gutiérrez-Mercado YK, Márquez-Aguirre AL, Canales-Aguirre AA. Potential Effects of MSC-Derived Exosomes in Neuroplasticity in Alzheimer's Disease. *Front Cell Neurosci.* 2018;12(September):1–16.
50. Vasic V, Barth K, Schmidt MHH. Neurodegeneration and neuro-regeneration—Alzheimer's disease and stem cell therapy. *Int J Mol Sci.* 2019;20(17).
51. Elia CA, Losurdo M, Malosio ML, Coco S. Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid - β , Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures? 2019;1800199:1–10.
52. Ferreira A, Camargo C, Premer C, Hare JM, Baumel BS, Pinto M. Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease. *Exp Neurol* [Internet]. 2021;341:113706. Available from: <https://doi.org/10.1016/j.expneurol.2021.113706>
53. Stefańska K, Ożegowska K, Hutchings G, Popis M, Moncrieff L, Dompe C, et al. Human Wharton's Jelly—cellular specificity, stemness potency, animal models, and current application in human clinical trials. *J Clin Med.* 2020;9(4).
54. Dabrowska S, Sypecka J, Jablonska A, Strojek L, Wielgos M, Domanska-Janik K, et al. Neuroprotective Potential and Paracrine Activity of Stromal Vs. Culture-Expanded hMSC Derived from Wharton Jelly under Co-Cultured with Hippocampal Organotypic Slices. *Mol Neurobiol.* 2018;55(7):6021–36.
55. Yarni SD. Pengaruh Pemberian Mesenchymal Stem Cells Wharton Jelly Terhadap Ekspresi Gen CALM1 dan CASP9 pada Tikus Alzheimer. *Andalas University*; 2021.
56. Sun C, Wang L, Wang H, Huang T, Yao W, Li J, et al. Single-cell RNA-seq highlights heterogeneity in human primary Wharton's jelly mesenchymal stem/stromal cells cultured in vitro. *Stem Cell Res Ther.* 2020;11(1):1–16.
57. Kangari P, Talaei-Khozani T, Razeghian-Jahromi I, Razmkhah M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. *Stem Cell Res Ther.* 2020;11(1):1–21.
58. Myers A, Mcgonigle P. Overview of Transgenic Mouse Models for Alzheimer's Disease. 2019;89:1–21.
59. Mustafa HN. Neuro-amelioration of cinnamaldehyde in aluminum-induced Alzheimer's disease rat model. *J Histotechnol* [Internet]. 2020;43(1):11–20.

Available from: <https://doi.org/10.1080/01478885.2019.1652994>

60. Ali AA, Khalil MG, El-latif DMA, Okda T, Abdelaziz AI, Kamal MM, et al. The influence of vinpocetine alone or in combination with Epigallocatechin-3-gallate , Coenzyme COQ10 , Vitamin E and Selenium as a potential neuroprotective combination against aluminium-induced Alzheimer ' s disease in Wistar Albino Rats. Arch Gerontol Geriatr [Internet]. 2022;98(October 2021):104557. Available from: <https://doi.org/10.1016/j.archger.2021.104557>
61. Kristianingrum YP, Widyarini S, Sutrisno B, Patologi D, Hewan FK, Mada UG. Gambaran Histopatologi Otak Tikus Akibat Injeksi Trimetyltin sebagai Model Penyakit Alzheimer. J Sain Vet. 2017;34(1):84–91.
62. WHO. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization. 2000;1–73. Available from: http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf (Accessed 09.09.2016)
63. Aboelwafa HR, El-Kott AF, Abd-Ella EM, Yousef HN. The possible neuroprotective effect of silymarin against aluminum chloride-prompted alzheimer's-like disease in rats. Brain Sci. 2020;10(9):1–21.
64. Kim H, Na DL, Lee NK, Kim AR, Lee S, Jang H. Intrathecal injection in a rat model: A potential route to deliver human wharton's jelly-derived mesenchymal stem cells into the brain. Int J Mol Sci. 2020;21(4):1–11.
65. Pawitan JA. Aspek Biologi, Pemrosesan dan Aplikasi Klinis Sel Punca Mesenkimal [Internet]. Mubarak W, editor. Jakarta: Continuing Medical Education-Continuing Professional Development (CME-CPD) Unit Fakultas Kedokteran Universitas Indonesia; 2018. 64 p. Available from: https://staff.ui.ac.id/system/files/users/decky/publication/buku_aspek_biologi_pemrosesan_dan_aplikasi_klinis_sel_punca_mesenkimal.pdf
66. Indrianti M. Deteksi Kandungan Babi Pada Produk Olahan Daging Menggunakan Metode Multipleks Pcr Di Kabupaten Pandeglang. Biodidaktika J Biol Dan Pembelajarannya. 2021;16(1).
67. Wang AYL, Loh CY, Shen HH, Hsieh SY, Wang IK, Lee CM, et al. Human wharton's jelly mesenchymal stem cell-mediated sciatic nerve recovery is associated with the upregulation of regulatory t cells. Int J Mol Sci. 2020;21(17):1–14.
68. Bodart-Santos V, De Carvalho LRP, De Godoy MA, Batista AF, Saraiva LM, Lima LG, et al. Extracellular vesicles derived from human Wharton's jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid- β oligomers. Stem Cell Res Ther. 2019;10(1):1–13.
69. Sivandzade F, Cucullo L. Regenerative stem cell therapy for

neurodegenerative diseases: An overview. *Int J Mol Sci.* 2021;22(4):1–21.

70. Costa LA, Eiro N, Fraile M, Gonzalez LO, Saá J, Garcia-Portabella P, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. *Cell Mol Life Sci* [Internet]. 2021;78(2):447–67. Available from: <https://doi.org/10.1007/s00018-020-03600-0>
71. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. *Cells.* 2019;8(12).
72. Li B, Gao Y, Zhang W, Xu JR. Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease. *J Neurosci Res.* 2018;96(5):828–40.
73. Garcia-Contreras M, Thakor AS. Human adipose tissue-derived mesenchymal stem cells and their extracellular vesicles modulate lipopolysaccharide activated human microglia. *Cell Death Discov* [Internet]. 2021;7(1). Available from: <http://dx.doi.org/10.1038/s41420-021-00471-7>

